Advertisement

The Churg—Strauss Syndrome

  • Andrew Churg
  • Ulrich Specks
  • John H. Stone

Abstract

The Churg—Strauss Syndrome (CSS) is a form of necrotizing vasculitis characterized by eosinophilic infiltration of small- and medium-sized blood vessels. The initial disease manifestation is usually the development of asthma in an individual who did not suffer previously from reactive airway disease. Allergic rhinitis is another manifestation of atopy, often identified in retrospect as the first sign of CSS. The extra-pulmonary organs commonly involved in the CSS are the peripheral nerves, skin, joints, and heart. The brain, eyes, gastrointestinal tract, and kidneys are involved less often. Vasculitic neuropathy occurs in 80% of patients with CSS and can lead to devastating complications through paralysis of the distal extremities. Nerve infarctions generally lead to an asymmetric, axonal sensorimotor neuropathy. The clinical features of CSS overlap in many ways on those of two other forms of necrotizing vasculitis, Wegener's granulomatosis, and microscopic poly-angiitis. However, patients with CSS are less likely to have antineutrophil cytoplasmic antibodies (ANCA) than those with other conditions. When patients with CSS are ANCA-positive, the antigen specificity is directed more often against myeloperoxidase than against serine proteinase-3. Anti-myeloperoxidase ANCA produces a perinuclear (“P-ANCA”) pattern of staining in immunofluorescence studies of serum. CSS must be distinguished from a group of non-vasc-ulitic conditions associated with hypereosinophilia. Among these are the hypereosinophil syndrome, eosinophilic leukemia, eosinophilic fasciitis, and parasitic infections.

Keywords

Allergic Rhinitis Diffuse Alveolar Hemorrhage Hypereosinophil Syndrome Rheumatoid Nodule Necrotizing Vasculitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Boin F, Sciubba JJ, Stone JH. Churg-Strauss syndrome presenting with salivary gland enlargement and respiratory distress. Arthritis Rheum 2006; 55:167–170PubMedCrossRefGoogle Scholar
  2. Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol 2001; 14:1284–1293PubMedCrossRefGoogle Scholar
  3. Churg A. Churg-Strauss syndrome, microscopic polyangiitis, and other forms of pulmonary vasculitis. In: Churg A, Myers J, Tazelaar H, Wright JL (eds) Thurlbeck's pathology of the lung (3rd edn). New York, Thieme Medical Publishers, 2005, pp. 391–412Google Scholar
  4. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and peri-arteritis nodosa. Am J Pathol 1951; 27:277–301PubMedGoogle Scholar
  5. Clutterbuck E, Evans D, Pusey C. Renal involvement in Churg-Strauss syndrome. Nephrol Dial Transplant 1990; 5:161–167PubMedCrossRefGoogle Scholar
  6. Dahabreh IJ, Giannouli S, Zoi C, et al Management of hypereosino-philic syndrome: A prospective study in the era of molecular genetics. Medicine (Baltimore) 2007; 86(6):344–354CrossRefGoogle Scholar
  7. Godman G, Churg J. Wegener's granulomatosis: Pathology and review of the literature. Arch Pathol Lab Med 1954; 58:533–551Google Scholar
  8. Guillevin L, Cohen P, Gayraud M, et al Churg-Strauss syndrome: Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26–37CrossRefGoogle Scholar
  9. Keogh KA, Specks U. Churg-Strauss syndrome: Clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284–290PubMedCrossRefGoogle Scholar
  10. Lanham JG, Elkon KB, Pusey CD, Hughes GRV. Systemic vasculitis with asthma and eosinophilia: A clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63:65–81Google Scholar
  11. Mathew L, Talbot K, Love S, et al Treatment of vasculitic peripheral neuropathy: A retrospective analysis of outcome. Q J Med 2007; 100:41CrossRefGoogle Scholar
  12. Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19:25–32PubMedCrossRefGoogle Scholar
  13. Rothenberg ME, Klion AD, Roufosse FE, et al Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358(12):1215–1228PubMedCrossRefGoogle Scholar
  14. Sablé-Fourtassou R, Cohen P, Mahr A, et al Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632–638PubMedCrossRefGoogle Scholar
  15. Sinico RA, Di Toma L, Maggiore U, et al Prevalence and clinical sig-nificance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52: 2926–2935PubMedCrossRefGoogle Scholar
  16. Wechsler ME. Combating the eosinophil with anti-interkeukin-5 therapy. N Engl J Med 2008; 358(12):1293–1294PubMedCrossRefGoogle Scholar
  17. Wechsler ME, Finn D, Gunawardena D, et al Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117:708–713PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Andrew Churg
    • 1
  • Ulrich Specks
    • 2
  • John H. Stone
    • 3
  1. 1.Department of PathologyUniversity of British ColumbiaCanada
  2. 2.Division of Pulmonary and Critical Care MedicineMay ClinicRochesterUSA
  3. 3.Massachusetts General HospitalRheumatology

Personalised recommendations